These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30124521)

  • 1. T lymphocytes as therapeutic arsenal for patients with hematological malignancies.
    Montoro J; Piñana JL; Sanz J; Guerreiro M
    Curr Opin Oncol; 2018 Nov; 30(6):425-434. PubMed ID: 30124521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicities associated with immunotherapies for hematologic malignancies.
    Leick MB; Maus MV
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):158-165. PubMed ID: 29909916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.
    Perales MA; Sauter CS; Armand P
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):17-22. PubMed ID: 26485445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive therapy with CAR redirected T cells for hematological malignancies.
    Li S; Yang Z; Shen J; Shan J; Qian C
    Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
    Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X
    J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in T-cell immunotherapy for haematological malignancies.
    Rouce RH; Sharma S; Huynh M; Heslop HE
    Br J Haematol; 2017 Mar; 176(5):688-704. PubMed ID: 27897332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
    Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
    Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taking a BiTE out of the CAR T space race.
    Patel A; Oluwole O; Savani B; Dholaria B
    Br J Haematol; 2021 Dec; 195(5):689-697. PubMed ID: 34131894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapeutic potential of NK and NKT cell lines in hematopoietic malignancies.
    Hu Z
    Leuk Res; 2003 Oct; 27(10):879-81. PubMed ID: 12860005
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic Advances in Immunotherapies for Hematological Malignancies.
    Nogami A; Sasaki K
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing immunotherapy for pediatric T-cell malignancies.
    Diorio C; Teachey DT
    Expert Rev Clin Immunol; 2020 Apr; 16(4):361-371. PubMed ID: 32103690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific Adoptive Cellular Immunotherapy in Allogeneic Stem Cell Transplantation.
    Audehm S; Krackhardt AM
    Oncol Res Treat; 2017; 40(11):691-696. PubMed ID: 29069663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
    Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
    Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction to a review series on emerging immunotherapies for hematologic diseases.
    Paczesny S; Pavletic SZ; Bollard CM
    Blood; 2018 Jun; 131(24):2617-2620. PubMed ID: 29728405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.
    Liu J; Zhong JF; Zhang X; Zhang C
    J Hematol Oncol; 2017 Jan; 10(1):35. PubMed ID: 28143567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis.
    Kean LS
    Blood; 2018 Jun; 131(24):2630-2639. PubMed ID: 29728399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adoptive immunotherapy using gene-modified T cells to express target-specific receptors against hematological malignancy].
    Fujiwara H
    Rinsho Ketsueki; 2014 Oct; 55(10):2162-74. PubMed ID: 25297783
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment.
    Cosenza M; Sacchi S; Pozzi S
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!
    Grant ML; Bollard CM
    Blood Rev; 2018 May; 32(3):203-224. PubMed ID: 29198753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.